AbbVie

Update in progress

ABBV (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

AbbVie is a research-based biopharmaceutical company that discovers, develops, manufactures, and markets medicines and therapies worldwide. Its portfolio includes Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Epkinly, Emrelis, Botox Cosmetic, Juvederm, Vraylar, Duodopa, Ubrelvy, Qulipta, Vyalev, Botox Therapeutic, Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Refresh/Optive, Xen, Durysta, Restasis, Mavyret, Creon, and Linzess/Constella. Based in North Chicago, IL, since 2012.

Company score

Sentiment: 2.53; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.09; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 2.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.66; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.79; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.66; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive